In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1852 News Items found
Former MSK president Paul Marks
Feature
The Man behind the Prize: How Paul Marks Shaped Modern Cancer Research

Recent advances in epigenetic and targeted therapies owe a lot to the foresight of former MSK President Paul Marks, who believed in the importance of basic research.
Thanksgiving dinner
Feature
How to Cope with Holiday Stress When You Have Cancer

Read our suggestions for getting through the holiday season while facing cancer.
FDA Announces First Approval of Targeted Therapy Based on Basket Study

The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).
iron-filled macrophages from a breast cancer tumor
In the Lab
MSK-Developed Technology Provides a “Virtual Biopsy” of Immune Cells in Tumors

The noninvasive approach could help scientists track the movements of an important cell type that can influence the outcome of cancer treatment.
Cancer biologist and pediatric oncologist Alex Kentsis
Science Byte
Blocking Enzymes That Signal DNA Damage Could Be a Treatment Strategy for Childhood Cancers

A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.
Shawn, a Fred’s Team runner
Event
Why They Run: Fred’s Team Runners Take on the 2017 TCS New York City Marathon

Hear from five Fred’s Team members about why they’re running the New York City Marathon in 2017.
MSK Integrative Medicine meditation instructor Emily Herzlin
Q&A
How Meditation Can Help Those Affected by Cancer: At Work with Emily Herzlin

Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.
A new study suggests that healthcare providers should consider looking for monoclonal gammopathy of undetermined significance (MGUS) in younger African Americans.
Finding
Myeloma Precursor Disease Can Start Much Earlier than Expected, Especially in African Americans

New research has found that a precancerous blood condition can linger undetected for more than 20 years.
Memorial Sloan Kettering medical oncologist Paul Hamlin
Announcement
FDA Approves CAR T Cell Therapy for Non-Hodgkin Lymphoma

This is the second regulatory approval of the cell-based immunotherapy for a blood cancer.
Stem cells induced to become cardiomyocytes
In the Lab
Stem Cell Research Probes Why a Breast Cancer Treatment Sometimes Damages the Heart

Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.